Fluticasone propionate inhalation - Teva Pharmaceutical Industries

Drug Profile

Fluticasone propionate inhalation - Teva Pharmaceutical Industries

Alternative Names: ArmonAirTM RespiClick; Fluticasone propionate MDPI; Fluticasone propionate MDPI - Teva Pharmaceutical Industries; Fluticasone propionate RespiClick®

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Asthma

Most Recent Events

  • 06 Mar 2017 Updated efficacy data from a phase III trial in Asthma presented at the 2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2017)
  • 30 Jan 2017 Registered for Asthma (In adolescents, In adults) in USA (Inhalation)
  • 01 Dec 2016 Phase-III clinical trials in Asthma (In children) in USA (Inhalation) (NCT02980133)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top